Mesenchymal stem cells RNA silencing guide

MSCs present unique biological barriers that compromise conventional gene delivery methods:

Loss of multipotency with transfection

Lipofection and electroporation can trigger spontaneous differentiation in MSCs. Cationic lipids may activate intracellular calcium signaling and stress-activated protein kinase pathways (p38 MAPK, JNK) that can induce lineage commitment, particularly toward osteogenic differentiation. Treated cells may show increased alkaline phosphatase activity, upregulation of RUNX2, and in some cases, early mineralization markers even without differentiation-inducing media. This loss of stemness compromises the study of MSC biology, as cells no longer represent true multipotent stromal cells. Colony-forming unit-fibroblast (CFU-F) capacity frequently shows substantial reduction post-transfection.

High impact

Extreme donor heterogeneity

MSCs from different donors show significant variation in transfection efficiency with identical protocols. This heterogeneity stems from multiple factors including donor age (efficiency typically decreases with age), tissue source (bone marrow vs adipose vs umbilical cord), passage number (efficiency typically drops after passages 3-4), and individual biological variation. Younger donor umbilical cord MSCs may achieve higher transfection efficiency compared to aged donor bone marrow MSCs. This variability makes standardized protocols challenging and often requires optimization for different donor sources.

High impact

Induction of premature senescence

Electroporation and harsh transfection conditions can trigger stress-induced premature senescence (SIPS) in MSCs. Treated cells may exhibit senescence hallmarks including enlarged, flattened morphology, increased senescence-associated β-galactosidase (SA-β-gal) activity, upregulation of cell cycle inhibitors (p16INK4a/CDKN2A and p21CIP1/CDKN1A), reduced proliferation or growth arrest, and development of a senescence-associated secretory phenotype (SASP) characterized by increased secretion of pro-inflammatory factors including IL-6, IL-8, and matrix metalloproteinases. Senescent MSCs typically show reduced therapeutic efficacy and limited expansion potential for research or clinical applications.

High impact

Compromised immunomodulatory function

Transfection can disrupt MSC immunosuppressive capacity: a key therapeutic mechanism. Lipofection has been reported to reduce IDO (indoleamine 2,3-dioxygenase) activity, potentially decrease PGE2 secretion, and may impair T cell suppression capacity in mixed lymphocyte reaction (MLR) assays. The cellular stress from transfection can alter the MSC secretome, potentially shifting the balance from anti-inflammatory to pro-inflammatory mediators, with possible increases in cytokines such as IL-1β, IL-6, or TNF-α. This functional alteration can compromise immunomodulation studies and therapeutic applications.

High impact

Altered secretome and EV production

MSC therapeutic efficacy depends on secreted factors and extracellular vesicles (EVs/exosomes). Transfection can alter this secretome, potentially affecting growth factor secretion (VEGF, HGF, IGF-1, FGF-2), EV size distribution and cargo content (proteins, RNAs, lipids), total EV production levels, and surface marker expression on EVs that determines targeting specificity. Since MSC-EVs are being developed as cell-free therapeutics for various indications, maintaining authentic EV production profiles is important for translational research.

Medium impact

Limited expansion post-transfection

MSCs have finite replicative capacity (Hayflick limit), typically undergoing 15-50 population doublings before senescence depending on source and culture conditions. Transfection stress may accelerate progression toward this limit: cells may show reduced proliferation rates at earlier passages, population doubling time can increase substantially, and clonogenic capacity (CFU-F) frequently decreases. For research requiring extensive expansion or therapeutic applications requiring large cell doses, this limited expansion potential can be a significant constraint.

High impact

Method comparison

AUMsilence™ sdASO™

Why AUMsilence™ sdASOs™ suit MSCs

Key benefits

• No transfection required
  Added to the culture medium. No transfection reagent, electroporation, or viral vector is needed.
• Knockdown efficiency
  Gene silencing across MSC sources: bone marrow, adipose, umbilical cord, and dental pulp MSCs, at 70-95% knockdown.
• Differentiation capacity
  Osteogenic, adipogenic and chondrogenic differentiation are read on the treated cells, by lineage-specific staining and gene expression.
• Colony formation
  CFU-F capacity is read on the treated cells against a passage-matched untreated control.
• Passage capability
  No electric pulse is applied, so the premature senescence electroporation can trigger is not introduced. Population doubling time is read across passages against a passage-matched control.
• Scalable protocol
  No delivery equipment is used, so the protocol scales with the culture volume.

Cell types and applications

• Primary human MSCs from all tissue sources
• Differentiation mechanism studies
• Immunomodulation pathway dissection
• Senescence and aging research
• Enhancement strategy studies
• Exosome/EV cargo modification
• Disease modeling applications
• Tissue engineering optimization
• Preclinical MSC studies

• AUMsilence™ sdASO™

Alternative products

• AUMlnc™ sdASO™ When to use: For targeting nuclear lncRNAs involved in MSC epigenetic regulation and chromatin remodeling.
• AUMantagomir™ sdASO™ When to use: For inhibiting microRNAs regulating MSC differentiation and therapeutic properties.

Optimized protocols for bone marrow, adipose, and umbilical cord MSCs. No transfection reagents required; preserves stemness.

Quick start protocol (all MSC sources)

1. 01Culture MSCs at 3-5 × 10³ cells/cm² in appropriate medium (DMEM + 10% FBS)
2. 02Add AUMsilence™ sdASO™ directly to culture medium at 10 μM (no transfection reagent)
3. 03Incubate 48-72 hours at 37°C, 5% CO₂
4. 04Validate knockdown by qRT-PCR (mRNA at 48h) and Western blot (protein at 72h)
5. 05Confirm maintained stemness by trilineage differentiation or CFU-F assay

Cell-type-specific protocols

Bone marrow-derived MSCs (BM-MSCs)

1. 01

   Step 1: MSC culture setup

   Thaw or passage BM-MSCs (P2-P6 optimal). Seed at 3-5 × 10³ cells/cm² in T75 flask or 6-well plate. Use complete medium: DMEM low glucose + 10% MSC-qualified FBS + 1% Pen/Strep + 2 mM L-glutamine. Allow 24h for attachment and spreading.

   Materials: DMEM low glucose, MSC-qualified FBS, culture vessels

   Note: Use MSCs between passages 2-6. Higher passages show reduced efficiency.

   Timing: Day -1

2. 02

   Step 2: AUMsilence sdASO treatment

   When MSCs reach 50-70% confluence, add AUMsilence sdASO directly to culture medium at 10 μM final concentration. For 10 mL medium in T75 flask, add 100 μL of 1 mM stock. Mix gently by swirling. No medium change needed.

   Materials: AUMsilence sdASO (1 mM stock in nuclease-free water)

   Note: AUMsilence sdASOs are taken up by endocytosis.

   Timing: Day 0

3. 03

   Step 3: Incubation period

   Incubate at 37°C, 5% CO₂ for 48-72h. Monitor daily for confluence and morphology. MSCs should maintain spindle shape and plastic adherence. If approaching 80% confluence, passage as normal (ASO will be diluted but knockdown maintained).

   Materials: Humidified CO₂ incubator

   Note: mRNA knockdown is typically achieved 24-72 hours after treatment. No morphological changes expected.

   Timing: Days 0-3

4. 04

   Step 4: Knockdown validation

   At 48h: harvest subset for qRT-PCR, expect 70-95% knockdown. At 72h: harvest for Western blot or flow cytometry for protein reduction. Save remaining cells for functional assays.

   Materials: RNA extraction kit, qPCR reagents, protein analysis tools

   Note: Include reference genes: GAPDH, ACTB for qPCR; β-actin, GAPDH for Western.

   Timing: Days 2-3

5. 05

   Step 5: Stemness validation

   Perform trilineage differentiation: Osteogenic (21 days, Alizarin Red staining), Adipogenic (14 days, Oil Red O staining), Chondrogenic (21 days, Alcian Blue staining). Or perform CFU-F assay: replate at 100 cells/10cm dish, count colonies after 14 days.

   Materials: Differentiation media kits, staining reagents

   Note: Compare with untreated MSCs differentiated in parallel.

   Timing: Days 3-24

Adipose-derived MSCs (AD-MSCs)

1. 01

   Step 1: AD-MSC culture

   Culture AD-MSCs in DMEM/F12 + 10% FBS + 1 ng/mL bFGF. Seed at 4-6 × 10³ cells/cm² (AD-MSCs proliferate faster than BM-MSCs). Allow 24h attachment.

   Materials: DMEM/F12, FBS, bFGF

   Note: AD-MSCs may show higher baseline proliferation rate.

   Timing: Day -1

2. 02

   Step 2: AUMsilence sdASO treatment

   Add AUMsilence sdASO at 10 μM to 60-70% confluent cultures. AD-MSCs may show slightly faster uptake due to higher metabolic activity.

   Materials: AUMsilence sdASO

   Note: Some targets may achieve good knockdown at lower concentrations in AD-MSCs.

   Timing: Day 0

3. 03

   Step 3: Functional validation

   Besides standard knockdown validation, test immunomodulation: co-culture with activated PBMCs (1:10 ratio), measure T cell proliferation suppression.

   Materials: PBMCs, CFSE, flow cytometer

   Note: Measure suppression against untreated AD-MSCs in the same assay.

   Timing: Days 3-5

Umbilical cord MSCs (UC-MSCs)

1. 01

   Step 1: UC-MSC culture

   Culture UC-MSCs in DMEM low glucose + 10% FBS. These cells show rapid proliferation (doubling time 20-30h) and may reach confluence quickly. Seed at 2-3 × 10³ cells/cm².

   Materials: DMEM low glucose, FBS

   Note: UC-MSCs from Wharton's jelly show most consistent properties.

   Timing: Day -1

2. 02

   Step 2: Optimized ASO delivery

   Due to rapid proliferation, UC-MSCs may dilute ASO faster. Consider: dialing up from 10 μM for highly stable targets, or re-dosing every 3 to 5 days if extending culture beyond 72h.

   Materials: AUMsilence sdASO

   Timing: Day 0

3. 03

   Step 3: Extended culture applications

   For long-term studies (>72h): Re-dose every 3 to 5 days. Split cells as needed maintaining ASO in new medium.

   Materials: Standard culture reagents

   Note: Read knockdown at each passage against a non-targeting control.

   Timing: Days 3+

Essential controls

• Untreated MSCs: Baseline for gene expression and functional assays
  Culture identically without ASO addition
• Non-targeting control ASO: Control for ASO-specific effects
  Use AUM non-targeting control at same concentration
• Differentiation control: Verify maintained multipotency
  Perform trilineage differentiation on treated vs untreated MSCs
• Passage-matched control: Account for passage-related changes
  Use MSCs at same passage number for all experiments

Optimization strategies

Troubleshooting

Validation covers the target transcript and protein, the MSC surface markers, trilineage differentiation, colony formation and senescence. Where the target itself governs differentiation or immunomodulation, a change in these readouts is the expected phenotype.

Trilineage differentiation assay

Flow cytometry panel

Colony forming unit-fibroblast (CFU-F)

T cell suppression assay

Senescence-associated β-galactosidase

qRT-PCR validation

Western blot

Critical controls for MSC experiments

• Passage-matched untreated MSCs
  Purpose: Baseline for all measurements
  Use same passage number, culture conditions, and donor.
• Non-targeting control ASO
  Purpose: ASO-specific effects control
  Same concentration and timing as experimental ASO.
• Differentiation medium only
  Purpose: Spontaneous differentiation control
  MSCs in differentiation medium without ASO.
• Multiple donors
  Purpose: Account for donor variability
  Use n≥3 different donors for key experiments.
• Early vs late passage
  Purpose: Passage effect control
  Compare P3 vs P7 for passage-dependent changes.

Best practices

• Always verify MSC identity by flow cytometry before experiments
• Use MSCs between passages 2-6
• Perform trilineage differentiation to confirm multipotency maintenance
• Include CFU-F assay to assess clonogenic capacity
• Test immunomodulatory function if relevant to study goals
• Monitor for senescence markers especially in extended cultures
• Validate both mRNA (48h) and protein (72h) knockdown
• Use multiple donors to ensure reproducibility
• Document passage number, source tissue, and donor age